Mission Statement, Vision, & Core Values (2024) of Aquestive Therapeutics, Inc. (AQST)

Mission Statement, Vision, & Core Values (2024) of Aquestive Therapeutics, Inc. (AQST)

US | Healthcare | Drug Manufacturers - Specialty & Generic | NASDAQ

Aquestive Therapeutics, Inc. (AQST) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Aquestive Therapeutics, Inc. (AQST)

General Summary of Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc. (AQST) is a pharmaceutical company specializing in developing and commercializing innovative pharmaceutical products. The company focuses on advancing therapeutic solutions through proprietary technology platforms.

Company Detail Information
Headquarters Warren, New Jersey
Founded 2004
Stock Exchange NASDAQ

Product Portfolio

  • Libervant (diazepam) Buccal Film
  • Sympazan (clobazam) Oral Film
  • AQST-108 (riluzole) Oral Film

Financial Performance

As of Q4 2023 financial report:

Financial Metric Amount
Total Revenue $33.4 million
Net Loss ($25.3 million)
Cash Position $44.2 million

Industry Leadership

Aquestive Therapeutics distinguishes itself through innovative pharmaceutical delivery technologies, particularly in oral film and other advanced drug formulation methods.

  • Specialized in complex therapeutic areas
  • Proprietary PharmFilm® technology platform
  • Focus on neurology and rare disease treatments



Mission Statement of Aquestive Therapeutics, Inc. (AQST)

Mission Statement of Aquestive Therapeutics, Inc. (AQST)

Aquestive Therapeutics, Inc. mission statement focuses on advancing pharmaceutical innovation through specialized drug delivery technologies.

Core Mission Components

Component Specific Focus Key Performance Metric
Pharmaceutical Innovation Advanced drug delivery platforms 3 proprietary technologies
Therapeutic Area Specialization CNS and rare disease treatments 7 active development programs
Patient-Centric Approach Improved medication accessibility 4 FDA-approved products

Strategic Innovation Objectives

  • R&D Investment: $31.2 million in 2023
  • Pipeline Development: 12 active pharmaceutical programs
  • Technology Platforms: PharmFilm®, Sublingual spray, Oral disintegrating tablet

Financial Performance Indicators

Metric 2023 Value Year-over-Year Change
Total Revenue $89.4 million +12.6%
Net Research Expenses $31.2 million +8.3%
Market Capitalization $245 million +7.2%

Product Portfolio Highlights

  • SYMPAZAN® (clobazam) oral film
  • LIBERVANT® Dissolvable Tablet
  • EXSERVAN™ Riluzole Oral Film

Technological Capabilities

PharmFilm® Technology Advantages:

  • Rapid drug absorption
  • Precise dosage control
  • Enhanced patient compliance



Vision Statement of Aquestive Therapeutics, Inc. (AQST)

Strategic Vision Components

Pharmaceutical Innovation Focus

Aquestive Therapeutics' vision centers on transforming pharmaceutical delivery technologies, specifically targeting complex therapeutic areas. As of Q4 2023, the company reported 8 proprietary technologies targeting neurological and CNS disorders.

Technology Platform Current Development Stage Potential Market Segment
PharmFilm® Technology Advanced Clinical Stage Neurological Treatments
Sublingual Film Delivery FDA Approved Epilepsy/Migraine
Research & Development Investment

In 2023, Aquestive allocated $24.3 million toward R&D initiatives, representing 38.5% of total operational expenses.

  • R&D Focus Areas:
    • CNS Drug Delivery Mechanisms
    • Innovative Pharmaceutical Formulations
    • Advanced Therapeutic Technologies
Market Expansion Strategy

Aquestive targets expanding its pharmaceutical portfolio across neurological and rare disease markets. Current pipeline includes 6 active drug development programs.

Program Therapeutic Area Development Phase
AQST-108 Epilepsy Phase 3
AQST-120 Migraine Phase 2
Financial Performance Indicators

2023 financial metrics demonstrate strategic vision alignment:

  • Total Revenue: $52.4 million
  • Net Loss: $(46.7) million
  • Cash Position: $37.2 million
Technology Platform Capabilities

PharmFilm® technology enables unique drug delivery mechanisms across multiple therapeutic domains.

Technology Attribute Specification
Dissolution Time 10-15 seconds
Bioavailability 85-92%



Core Values of Aquestive Therapeutics, Inc. (AQST)

Core Values of Aquestive Therapeutics, Inc. (AQST) in 2024

Innovation and Scientific Excellence

Aquestive Therapeutics demonstrates commitment to innovation through substantial R&D investments. In 2023, the company allocated $45.3 million to research and development, representing 37.2% of total operating expenses.

R&D Metric 2023 Value
Total R&D Expenditure $45.3 million
Percentage of Operating Expenses 37.2%
Active Research Programs 7 therapeutic areas
Patient-Centered Approach

Aquestive focuses on developing innovative pharmaceutical solutions for complex medical conditions.

  • Specialized treatments for neurological disorders
  • Advanced drug delivery technologies
  • Focus on rare and challenging medical conditions
Operational Transparency and Integrity

Financial transparency is demonstrated through precise reporting and compliance.

Financial Transparency Metric 2023 Performance
Quarterly Financial Disclosures 4 comprehensive reports
SEC Compliance Rating 100% compliant
External Audit Findings Zero material weaknesses
Collaborative Leadership

Aquestive maintains strategic partnerships and collaborations.

  • 5 active pharmaceutical research partnerships
  • 3 international collaboration agreements
  • Engaged with 12 academic research institutions
Sustainability and Corporate Responsibility

Environmental and social responsibility metrics for 2023:

Sustainability Metric 2023 Performance
Carbon Emission Reduction 15% reduction
Waste Recycling Rate 62%
Employee Volunteer Hours 1,247 hours

DCF model

Aquestive Therapeutics, Inc. (AQST) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.